Early reports of development of PSMA-targeted (2S)-2-(3-(1-carboxy-5-(4-211At-astatobenzamido) pentyl)ureido)-pentanedioic acid ([211At]At-6) show that [211At]At-6 exhibited significant tumor growth delay and improved survival in a PSMA-positive xenograft as well as a micrometastatic model 142. This evidence concerns the gene FOLH1 and neoplasm.